ValiRx plc (LON:VAL – Get Free Report) hit a new 52-week low during trading on Wednesday . The company traded as low as GBX 1.60 ($0.02) and last traded at GBX 1.70 ($0.02), with a volume of 2493828 shares. The stock had previously closed at GBX 1.83 ($0.02).
ValiRx Stock Down 6.8 %
The company has a market cap of £2.25 million, a PE ratio of -91.25 and a beta of 0.59. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.27 and a current ratio of 2.64. The firm has a fifty day simple moving average of GBX 2.38 and a 200 day simple moving average of GBX 2.92.
About ValiRx
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Featured Stories
- Five stocks we like better than ValiRx
- Retail Stocks Investing, Explained
- This Is the Top Large-Cap Stock Insiders Are Buying
- What is the S&P/TSX Index?
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Stocks to Take Advantage of Rising Gold Prices
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
